AbbVie IL-23 inhibitor gains second indication for treatment of psoriatic arthritis

On November 17, 2021, AbbVie announced that the European Commission (EC) has approved the second indication of the interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab), as a single agent or in combination with methamine Pterin (MTX) is used to treat adults with active psoriatic arthritis that are inadequate or intolerant to one or more anti-rheumatic drugs (DMARDs) that alter the progression of the disease

Psoriatic arthritis is a heterogeneous, systemic inflammatory disease with hallmark manifestations in multiple systems (including joints and skin)

Skyrizi selectively blocks IL-23 by binding to the p19 subunit of IL-23

This approval is based on positive data obtained from two randomized, double-blind, multi-center, placebo-controlled Phase 3 clinical trials

▲Skyrizi's performance in the primary and secondary endpoints in two phase 3 clinical trials (picture source: reference [2])

Reference materials:

[1] AbbVie Expands Immunology Portfolio in the European Union with the European Commission Approval of Skyrizi® (risankizumab) for the Treatment of Adults with Active Psoriatic Arthritis.

[2] Risankizumab (SKYRIZI®) Phase 3 Results Demonstrate Improvements in Disease Activity Across Joint and Skin Symptoms Among Psoriatic Arthritis Patients.

(The original text has been deleted)